Malaria Clinical Trial
Official title:
The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania: Cluster Randomized Trial
Over one year period in an area with universal coverage of LLIN and ACT provision as the first-line treatment of malaria, the investigators intend to evaluate the impact of DL on malaria transmission as measured by the incidence of malaria parasitemia, the prevalence of moderate to severe anemia, and entomological parameters. Information on the relative cost-effectiveness estimates of DL and the community acceptability of DL will also be measured.
Vector control, together with prompt treatment with an artemisinin-based combination therapy
(ACT) for individuals diagnosed with malaria and intermittent preventive treatment in
pregnant women, is a critical component of malaria control in Africa. The two main vector
control interventions used in Africa are long-lasting insecticidal nets (LLINs) and indoor
residual spraying (IRS). LLINs are currently the mainstay of vector control and are believed
to have contributed to the recent dramatic decline in malaria cases. However, resistance to
the pyrethroid insecticides used in the bed nets has increased. The second main vector
control method, IRS, has been an extremely effective adjunct to LLINs; its usefulness is
threatened by the high cost of repeated applications and increasing mosquito resistance to
insecticides used for spraying.
A new product, durable lining (DL) treated with non-pyrethroid insecticides, has been
developed by Vestergaard, which theoretically mimics the effect of IRS but is designed to
last for a minimum of three years. The product consists of a mixture of two non-pyrethroid
insecticides incorporated into a polymer fabric that are designed to migrate differentially
over the lifetime of the product to ensure sustained bioefficacy. The use of two agents may
also decrease the risk of development of resistance. It is estimated that the cost of the
insecticide treated wall liners (DL), which are installed on the indoor walls of houses,
would be equal to 2-3 rounds of IRS.
To test the effectiveness of this new product, we will conduct a two-arm controlled
randomized cluster trial to test the hypothesis that DL + LLINs are superior to LLINs alone.
Over twelve (12) months (August 2015- Aug 2016), in an area with universal coverage (UC) of
LLINs and where artemisinin combination therapies (ACT) are provided as the first-line
treatment of malaria, we intend to evaluate the impact of DL on malaria transmission among
children ages 6 months to 11 years as measured by the incidence of malaria parasitemia
(symptomatic and asymptomatic), and the prevalence of moderate to severe anemia in
under-fives. In addition, we will assess the effect of DL on entomological parameters, and
measure the acceptability and a cost-effectiveness of the intervention. Stratified
randomization based on malaria prevalence during the baseline survey will be used to select
22 clusters per arm in Muheza district.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |